Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016. “In the last 18 months, we have made important progress in moving forward both elements of our strategy, including our oncology pipeline, for which we have retained significant North American rights, and our non-oncology pipeline, which

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 12, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco. A live webcast can be accessed by visiting the investors section of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.m., before the Honorable Denise J. Casper, United States Courthouse, Courtroom No. 11 of the John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, Massachusetts 02210 in the matter of Karen J. van Ingen v. AVEO Pharmaceuticals, Inc., et al., Civil Action No. 1:14-cv-11672-DJC

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 6, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of

Download PDF –Phase 1/2 TiNivo Trial to Commence at the Institut Gustave Roussy in Paris- CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 4, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016. “The second quarter of 2016 marked a defining moment for AVEO, with the initiation of TIVO-3, our Phase 3 pivotal study of tivozanib in refractory advanced renal cell cancer, and the closing of debt and equity financings to

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York. A live webcast can be accessed by visiting the investors section of the Company’s

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 26, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor